A new set of clinical guidelines has been released to improve monitoring and early detection of bowel cancer among patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. The guidelines, developed for the British Society of Gastroenterology, are the result of a multi-institutional effort involving Newcastle University, Oxford University, the University of Central Lancashire, and others. The research is published in the UK journal Gut and was supported by the NIHR Biomedical Research Centres in Newcastle and Oxford.
Despite advancements in treatment and regular health monitoring, people with IBD continue to face significantly higher risks of developing and dying from colorectal cancer compared to the general population. The new guidelines provide evidence-based recommendations for risk assessment, colonoscopy timing, and surveillance protocols. Key among the recommendations is that all IBD patients undergo a colonoscopy around eight years after the onset of symptoms. Those with primary sclerosing cholangitis—a rare liver and bile duct condition often co-occurring with IBD—are advised to have a colonoscopy at the time of diagnosis.
The guidelines were shaped through an extensive review of over 7,500 scientific publications, resulting in 73 statements intended to guide clinicians in delivering effective surveillance services. Contributors included gastroenterologists, endoscopists, surgeons, specialist nurses, and patient representatives.
Professor Chris Lamb, Professor of Gastroenterology at Newcastle University and a co-author of the study, emphasized the patient-centered nature of the initiative. “Working in partnership with patients and clinicians, we’ve created a framework that combines the latest evidence, technology, and expert opinion to deliver personalized risk prediction and care,” he said.
Co-lead author Professor James East from Oxford University Hospitals NHS Foundation Trust noted that the guidelines offer clinicians comprehensive tools for tailoring care to individual patient needs. “They help clinicians determine when to begin or stop surveillance, how often to conduct it, and how to effectively communicate cancer risks with patients,” he said.
Professor Morris Gordon of the University of Central Lancashire, also a co-lead author, described the guidelines as a “significant shift in approach” due to their rigorous and transparent methodology in assessing clinical evidence.
Catherine Winsor, Director of Services and Evidence at Crohn's & Colitis UK, welcomed the guidelines, stating, “While most people with IBD will not develop colorectal cancer, early detection is crucial. These guidelines provide a clear path for timely diagnosis and improved outcomes.”
India is currently experiencing a sharp rise in IBD cases, especially in urban areas—a trend linked to factors such as changing diets, urbanisation, and improved sanitation. However, the country lacks standardized national guidelines for IBD management. Indian clinicians often rely on international frameworks, including those from the European Crohn’s and Colitis Organisation (ECCO). The newly released UK guidelines present an important opportunity for India to localize global best practices. Adoption and adaptation of these evidence-based recommendations could enhance early cancer detection, standardize IBD care, and ultimately improve outcomes for thousands of Indian patients.
Three foundational research papers have already been published to support the new guidelines: Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis; Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease; and Protocol for the 2024 British Society of Gastroenterology Guidelines on Colorectal Surveillance in IBD.
Newcastle University, a member of the UK’s Russell Group of research-intensive universities, is home to over 28,000 students from 130+ countries. The institution is recognized globally for its research excellence and is ranked 110th in the QS World University Rankings 2024 and 139th in the Times Higher Education World University Rankings 2023.
---
Full guidelines available at: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-335023
Comments